Now Playing
Opinion|Videos|July 8, 2024
Treatment Algorithm for Limited-Stage Small Cell Lung Cancer
Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.
Advertisement
Advertisement
Related to this article
Data presented at WCLC 2026 support the use of B7-H3–directed antibody-drug conjugates and brain MRI surveillance in small cell lung cancer.
The FDA reduced the recommended monitoring time for the first 2 doses of tarlatamab to 6 to 8 hours in extensive-stage small cell lung cancer.
Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5